Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031


Watson Says Received Favorable Ruling Over Generic Sanctura XR

04/03/2012 | 06:19pm US/Eastern

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108;

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
Recommend :
React to this article
Latest news on ACTAVIS INC
1d ago ACTAVIS : to Present at Morgan Stanley Global Healthcare Conference 2014
5d ago ACTAVIS : Confirms Generic Neupro® Patent Challenge
6d agoDJU.S. Restricts Narcotic Pain Drug Prescriptions
6d agoDJDEA Restricts Narcotic Pain Drug Prescriptions
6d ago Pfizer back for AstraZeneca? Year-end move seen most likely
08/19 ACTAVIS : Announces Positive Topline Results From The Phase III Program Of Cefta..
08/05DJU.S. HOT STOCKS : Hot Stocks to Watch
07/30 AstraZeneca buys Almirall lung drugs for up to $2.1 billion
07/28 Pfizer's need for deal looms larger with earnings report
07/21 ACTAVIS : Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for..
Dynamic quotes